HALF YEAR REPORT

Genetic Technologies Limited

Appendix 4D

Half-year ended 31 December 2025

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

Half-year ended: 31 December 2025

Previous period: 31 December 2024

Results for announcement to the market

		%		$
Revenue for ordinary activities	Down	100%	to	NIL
Loss after tax (from ordinary activities) for the period	Down	92%	to	(239,902)
Total comprehensive loss for the period attributable to members	Down	94%	to	(239,902)
Net tangible assets per security				

	31 December 2025 Cents	31 December 2024 Cents
Net tangible asset backing (per security)	(0.02)	(1.49)

Explanation of results

An explanation of the key financial elements contributing to the revenue and result above can be found in the review of operations included within the Directors' Report.

Distributions

No dividends have been paid or declared by the Company for the current financial period. No dividends were paid for the previous financial period.

Other information required by Listing Rule 4.2A

Details of individual and total dividends or distributions and dividend or distribution payments:	N/A
Details of any dividend or distribution reinvestment plans:	N/A
Details of associates and joint venture entities:	N/A
Other information:	N/A

Other disclosures and financial information

For other Appendix 4D disclosures, refer to the Half-year Financial Report for the period ended 31 December 2025 attached.

Genetic Technologies Limited

HALF YEAR REPORT

For the half-year ended
31 December 2025

Genetic Technologies Limited
ABN 17 009 212 328

Genetic Technologies Limited
ABN 17 009 212 328

Contents

Interim report for the half-year ended 31 December 2025

Contents	**Page**

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report should be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by Genetic Technologies Limited

The Directors submit the financial report on the consolidated entity consisting of Genetic Technologies Limited (ASX: GTG; "GTG" and the "Company") and the entities ("Group") it controlled at the end of, or during, the half-year ended 31 December 2025.

Directors

The following persons were Directors of Genetic Technologies Limited during the whole of the half-year and up to the date of this report:

Name	Position during period	Period of directorship
Michael Walker	Executive Chairman and Managing Director	Appointed 14 May 2025
William Musgrave	Non-executive director	Appointed 14 May 2025, resigned 24 March 2026
Anthony Hartman	Non-executive director	Appointed 14 May 2025, resigned 9 September 2025
Steve Nicols	Non-executive director	Appointed 19 December 2025, resigned 24 March 2026
Campbell Welch	Non-executive director	Appointed 24 March 2026
Jeffrey LeCompte	Non-executive director	Appointed 24 March 2026

Chief Financial Officer & Company Secretary

Jules Grove – Appointed as Chief Financial Officer on 14 May 2025, resigned 6 March 2026

Priyanvada (Pia) Rasal – Appointed as Joint Company Secretary on 14 May 2025

Review of operations

For the half-year ended 31 December 2025, the group incurred a loss before income tax of $239,902 (2024: $4,086,602) and net liabilities as at 31 December 2025 were $229,902 (30 June 2025: net assets $10,000). The group's cash position at 31 December 2025 was $10,257 (30 June 2025: $10,000).

The Group did not generate any customer receipts during the half-year to 31 December 2025 (2024: $3,455,457), reflecting the completion of the divestment of the Group's trading businesses during FY25 and the Company's status as a non-operating ASX-suspended shell during the period.

Background

The Group's financial records for the period of voluntary administration (20 November 2024 to 14 May 2025) were reconstructed by the Directors using data provided by the Administrators, and the Group completed the sale of its geneType, AffinityDNA and EasyDNA businesses during that period. On 14 May 2025 a deed of company arrangement was effectuated, recapitalising the Company and transitioning control to new directors. Full details are set out in the half-year and annual financial reports for the periods ended 31 December 2024 and 30 June 2025. The Group has not conducted any trading operations, and had no customer receipts, during the half-year ended 31 December 2025.

Significant changes in the state of affairs

During the half-year: on 9 September 2025 Anthony Hartman resigned as a non-executive director (publicly announced 19 December 2025); and on 19 December 2025 Steve Nicols was appointed as a non-executive director.
The Company's securities have been suspended from trading on ASX since 21 October 2024 and remained suspended throughout the half-year and as at the date of this report. The Company's ADRs were delisted from Nasdaq with effect from

17 December 2025.

Events since the end of the financial period

Since 31 December 2025 and up to the date of this report: on 6 March 2026 the Company announced the resignation of its Chief Financial Officer; on 24 March 2026 the Company announced it would not proceed with the proposed acquisitions of Ellerfield Wealth Pty Ltd and Walker Capital Private Wealth Pty Ltd, and William Musgrave and Steve Nicols resigned as non-executive directors and were replaced by Campbell Welch and Jeffrey LeCompte; on 22 June 2026 the Company's ADR facility was terminated; ASX issued further Long Term Suspended Entities notices on 17 April 2026 and 10 July 2026; on 24 August 2026 the Company's securities were suspended from official quotation for non-payment of annual listing fees; and on 31 August 2026 the FY25 Annual Report and Corporate Governance Statement were lodged with ASX. No other matter or circumstance has arisen since 31 December 2025 that has significantly affected or may significantly affect:

(a) the Group's operations in future years; or
(b) the results of those operations in future years; or
(c) the Group's state of affairs in future years.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 6.

This report is made in accordance with a resolution of Directors.

On behalf of the Board of Directors.

Michael Walker

Dated: 14 September 2026

Director
Sydney

GENETIC TECHNOLOGIES LIMITED
ABN 17 009 212 328

AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF GENETIC TECHNOLOGIES LIMITED

In accordance with Section 307C of the *Corporations Act 2001*, I am pleased to provide the following declaration of independence to the directors of Genetic Technologies Limited. As the lead audit partner for the review of the financial report of Genetic Technologies Limited for the half-year ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

i. the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and

ii. any applicable code of professional conduct in relation to the review.

HALL CHADWICK (NSW)
Level 40, 2 Park Street
Sydney, NSW 2000

DREW TOWNSEND
Partner
Dated: 14 September 2026

Condensed consolidated statement of profit or loss and comprehensive income for the half year ended 31 December 2025

	Notes	31 December 2025	31 December 2024
Continuing operations		**$**	**$**
Finance income		257	12,840
Other income		-	413,948
Employee benefits expenses		-	(938,405)
Professional fees		(218,375)	(280,975)
Depreciation and amortisation		-	(64,258)
Impairment expenses		-	(1,633,007)
Other expenses		(21,784)	(525,929)
Finance costs		-	(37,240)
Loss before income tax		**(239,902)**	**(3,053,026)**
Income tax expense		-	-
Loss for the period from continuing operations		**(239,902)**	**(3,053,026)**
Discontinued operations			
Loss from discontinued operations after tax		-	(1,033,576)
Loss for the period		**(239,902)**	**(4,086,602)**
Other comprehensive income			
Items that may be reclassified to profit or loss:			
Exchange (losses)/gains on translation of controlled foreign operations		-	(13,830)
Other comprehensive income for the period; net of tax		**-**	**(13,830)**
Total comprehensive loss for the period is attributable to:			
Owners of Genetic Technologies Limited		**(239,902)**	**(4,100,432)**
Loss per share for loss attributable to the ordinary equity holders of the Company:			
Basic/diluted loss per share (cents per share)	4	0.02	2.83
- Continuing operations		0.02	2.12
- Discontinued operations		-	0.72

The above condensed consolidated statement of profit or loss and comprehensive income should be read in conjunction with the accompanying notes.

Condensed consolidated statement of financial position
As at 31 December 2025

	Notes	31 December 2025 $	30 June 2025 $
ASSETS			
Current assets			
Cash and cash equivalents		10,257	10,000
Trade and other receivables		38,762	-
Total current assets		**49,019**	**10,000**
Total assets		**49,019**	**10,000**
LIABILITIES			
Current liabilities			
Trade and other payables		193,633	-
Borrowings	10	85,288	-
Total current liabilities		**278,921**	**-**
Total liabilities		**278,921**	**-**
Net (liabilities)/assets		**(229,902)**	**10,000**
EQUITY			
Share capital	3(a)	164,330,456	164,330,456
Reserves	3(c)	611,253	2,758,542
Accumulated losses		(165,171,611)	(167,078,998)
Total equity		**(229,902)**	**10,000**

The above condensed consolidated statement of financial position should be read in conjunction with the accompanying notes.

Condensed consolidated statement of changes in equity for the half-year 31 December 2025

	Notes	Share capital $	Other reserves $	Retained earnings $	Total equity $
Balance at 1 July 2025		164,330,456	2,758,542	(167,078,998)	10,000
Loss for the period		-		(239,902)	(239,902)
Other comprehensive gain		-	-	-	-
Total comprehensive income for the half-Year		-	-	(239,902)	(239,902)
Exercise of warrants, net of transactions Costs		-	-	-	-
Share based payments expense		-	-	-	-
Expiry of employee share options, warrants and performance rights		-	(2,147,289)	2,147,289	-
		-	-	-	-
Balance at 31 December 2025	3	**164,330,456**	**611,253**	**(165,171,611)**	**(229,902)**

	Notes	Share capital $	Other reserves $	Retained earnings $	Total equity $
Balance at 1 July 2024		163,817,863	4,388,628	(166,376,076)	1,830,415
Loss for the period		-		(4,086,602)	(4,086,602)
Other comprehensive gain		-	(13,830)	-	(13,830)
Total comprehensive income for the half-Year		-	(13,830)	(4,086,602)	(4,100,432)
Exercise of warrants, net of transactions Costs		139,602	(101,963)	-	37,639
Share based payments expense		-	63,407	-	63,407
Expiry of employee share options, warrants and performance rights		-	(760,356)	760,356	-
		139,602	(798,912)	760,356	101,046
Balance at 31 December 2024	3	**163,957,465**	**3,575,886**	**(169,702,322)**	**(2,168,971)**

The above condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Condensed consolidated statement of cash flows for the half-year 31 December 2025

		31 December 2025 $	31 December 2024 $
Cash flows from operating activities			
Receipts from customers		-	3,455,457
Payments to suppliers and employees		-	(5,365,750)
R&D tax incentive and other grants received		-	1,839,023
Net cash outflow from operating activities		-	(71,270)
Cash flows from investing activities			
Proceeds from sale of business	6	-	413,716
Payments for property, plant and equipment		-	(7,081)
Interest received		257	12,840
Net cash inflow from investing activities		257	419,475
Cash flows from financing activities			
Proceeds from issue of shares		-	37,611
Repayment of borrowings		-	(143,826)
Principal elements of lease payments		-	(160,565)
Interest paid		-	(86,042)
Net cash outflow from financing activities		-	(352,822)
Net increase/(decrease) in cash and cash equivalents		257	(4,617)
Cash and cash equivalents at the beginning of the financial period		10,000	1,020,608
Effects of exchange rate changes on cash and cash equivalents		-	(3,048)
Cash and cash equivalents at end of the half-year		10,257	1,012,943

The above condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

Note 1: Basis of preparation of half-year report

This condensed consolidated interim financial report for the half-year reporting period ended 31 December 2025 have been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001.

This interim report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by Genetic Technologies Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period and the adoption of the new and amended standards as set out below. The Interim Financial Statements have been approved and authorised for issue by the board of directors on 14 September 2026.

The consolidated financial statements of Genetic Technologies Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

Going concern

For the half-year ended 31 December 2025, the Company incurred a loss before income tax of $239,902. As at 31 December 2025, the Company had net liabilities of $229,902, cash and cash equivalents of $10,257, and net current liabilities of $229,902.

The financial statements have been prepared on a going concern basis. The Company's continuing viability is dependent on successful implementation of its recapitalisation strategy and its ability to secure additional funding to pursue investment opportunities and generate sustainable revenue streams. These conditions indicate a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern.

Note 2: Segment information

Following the disposal of the geneType business in December 2024 and the EasyDNA and AffinityDNA businesses in January 2025, the Company operates in one reportable segment.

The Company's activities during the half-year were primarily focused on corporate activities, debt and equity recapitalisation, and pursuing suitable investment opportunities. The Chief Executive Officer, as the chief operating decision maker, reviews the Company's financial performance and position on a consolidated basis. Accordingly, no separate segment information is presented.

Note 3: Equity

a. Quoted securities - movement in ordinary shares on issue

	Number of Ordinary Shares	Total $
Balance at 1 July 2025	1,335,422,460	164,330,456
Shares issued during the half financial year	-	-
At 31 December 2025	1,335,422,460	164,330,456

b. Unquoted securities - movement in performance rights, options and warrants

No unquoted performance shares, options or warrants were issued during the half-year ended 31 December 2025 (2024: NIL). No warrants were exercised during the period (2024: 13,200,000). 2,642,668 warrants expired (2024: 400,000), with associated $2,147,289 share-based payment reserve transferred to retained earnings (2024: $760,356)

	Performance Rights Number	Options and warrants Number	Total Number	Total $
Balance at 1 July 2025	-	4,630,168	4,630,168	2,758,542
Share based payments expense	-	-	-	-
Expired and transfer to retained earnings	-	(2,642,668)	(2,642,668)	(2,147,289)
Warrants exercised	-	-	-	-
At 31 December 2025	-	1,987,500	1,987,500	611,253

	Performance Rights Number	Options and warrants Number	Total Number	Total $
Balance at 1 July 2024	400,000	17,830,168	18,230,168	3,557,486
Share based payments expense	-	-	-	63,407
Expired and transfer to retained earnings	(400,000)	-	(400,000)	(760,356)
Warrants exercised	-	(13,200,000)	(13,200,000)	(101,963)
At 31 December 2024	-	4,630,168	4,630,168	2,758,574

Note 3: Equity (continued)

c. Other reserves

	Share based payments $	Foreign currency translation $	Total $
Balance at 1 July 2025	2,758,542	-	2,758,542
Currency translation differences	-	-	-
Other comprehensive income for the period	-	-	-
Share based payments expense	-	-	-
Expired performance rights, options and warrants	(2,147,289)	-	(2,147,289)
At 31 December 2025	611,253	-	611,253

	Share based payments $	Foreign currency translation $	Total $
Balance at 1 July 2024	3,557,486	831,142	4,388,628
Currency translation differences	-	(13,830)	(13,830)
Other comprehensive income for the period	-	(13,830)	(13,830)
Share based payments expense	63,407	-	63,407
Expired performance rights, options and warrants	(760,356)	-	(760,356)
Warrants exercised	(101,963)	-	(101,963)
At 31 December 2024	2,758,574	817,312	3,575,886

Note 4: Loss per share

a. Reconciliation of earnings used in calculating earnings per share

	31 December 2025	31 December 2024
	$	$
Basic earnings per share:		
Loss attributable to the ordinary equity holders of the Company used in calculating basic/diluted earnings per share:		
From continuing operations	(239,902)	(3,053,026)
From discontinued operations	-	(1,033,576)
	(239,902)	(4,086,602)

b. Weighted average number of shares used in denominator

	31 December 2025	31 December 2024
	Number	Number
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share *	1,335,422,460	144,269,420

* The calculation of diluted loss per share - potential ordinary shares are considered anti-dilutive, therefore diluted loss per share is equivalent to basic loss per share.

Note 5: Goodwill

The following table shows the movements in goodwill:

	31 December 2025	30 June 2025
	$	$
Gross carrying amount:		
Balance at beginning of period	-	4,961,893
Transfer to assets held for sale	-	(4,961,893)
Balance at end of period	-	-
Accumulated impairment:		
Balance at beginning of period	-	(3,177,000)
Impairment loss recognised	-	(1,298,516)
Transfer to assets held for sale	-	4,475,516
Balance at end of period	-	-
Carrying amount at the end of the period	-	-

Note 6: Discontinued operations

The geneType business was disposed of in December 2024, and the EasyDNA and AffinityDNA businesses were disposed of in January 2025. Accordingly, there were no discontinued operations during the half-year ended 31 December 2025.

The financial performance of the discontinued operations included in the comparative period was as follows:

	31 December 2025 $	31 December 2024 $
Revenue	-	3,373,587
Expenses	-	(4,407,163)
Loss before income tax	-	(1,033,576)
Income tax expense	-	-
Loss after tax	-	(1,033,576)

Note 7: Taxation

The Company has carried-forward tax losses as at 31 December 2025. These tax losses may be available to offset future taxable income, subject to the relevant tax loss recoupment requirements.

No deferred tax asset has been recognised in respect of these losses. The Company will reassess the recognition of deferred tax assets as its future operations develop.

Note 8: Dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Note 9: Contingent liabilities

The Company is not aware of any contingent liabilities as at 31 December 2025 and 31 December 2024.

Note 10: Related party transactions

Parent entities
Genetic Technologies Limited is the parent entity.

Transactions with other related parties
During the half-year, Nexis Advisory Pty Ltd, a related party, paid expenses totaling $85,288 on behalf of the Company, primarily relating to ASX fees, audit, legal and other corporate costs. These amounts have been recognised as loan payable to Nexis Advisory Pty Ltd.

Note 11: Events occurring after the reporting period

Since 31 December 2025 and up to the date of this report: on 6 March 2026 the Company announced the resignation of its Chief Financial Officer; on 24 March 2026 the Company announced it would not proceed with the proposed acquisitions of Ellerfield Wealth Pty Ltd and Walker Capital Private Wealth Pty Ltd, and William Musgrave and Steve Nicols resigned as non-executive directors and were replaced by Campbell Welch and Jeffrey LeCompte; on 22 June 2026 the Company's ADR facility was terminated; ASX issued further Long Term Suspended Entities notices on 17 April 2026 and 10 July 2026; on 24 August 2026 the Company's securities were suspended from official quotation for non-payment of annual listing fees; and on 31 August 2026 the FY25 Annual Report and Corporate Governance Statement were lodged with ASX. No other matter or circumstance has arisen since 31 December 2025 that has significantly affected or may significantly affect:

(a) the Group’s operations in future years; or
(b) the results of those operations in future years; or
(c) the Group’s state of affairs in future years.

In the Directors’ opinion:

a. the financial statements and notes set out on pages 7 to 16 are in accordance with the Corporations Act 2001, including:

   i complying with AASB 134 Interim Financial Reporting, the Corporations Regulations 2001 and other mandatory professional reporting requirements, and

   ii giving a true and fair view of the consolidated entity’s financial position as at 31 December 2025 and of its performance for the half-year ended on that date, and

b. there are reasonable grounds to believe that the Genetic Technologies Limited will be able to pay its debts as and when they become due and payable.

This declaration is signed in accordance with a resolution of Directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors

Michael Walker
Director
Sydney
Dated: 14 September 2026

GENETIC TECHNOLOGIES LIMITED
ABN 17 009 212 328

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF
GENETIC TECHNOLOGIES LIMITED

Qualified Conclusion

We have reviewed the half-year financial report of Genetic Technologies Limited (the company) and its controlled entities (the group), which comprises the consolidated statement of financial position as at 31 December 2025, the consolidated statement of profit and loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year then ended, a summary of material accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, except for the effects of the matter described in the Basis of Qualified Conclusion section of our report, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the group does not comply with the *Corporations Act 2001* including:

(a) giving a true and fair view of the group financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and

(b) complying with Accounting Standard AASB 134: *Interim Financial Reporting and the Corporations Regulations 2001*.

Basis for Qualified Conclusion

The comparative financial information for the half-year ended 31 December 2024 includes transactions undertaken while the company was under external administration from 20 November 2024 to 14 May 2025 pursuant to a Deed of Company Arrangement. During that period, the powers of the directors were suspended and control of the company's business, property and affairs rested with the appointed administrators.

As explained in our auditor's report on the financial report for the year ended 30 June 2025, the underlying accounting and statutory records for transactions during the period of external administration were not sufficiently maintained to enable us to obtain sufficient appropriate audit evidence regarding the income and expenses recognised during that period. Consequently, we were unable to determine whether any adjustments might have been necessary to the comparative amounts in the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended 31 December 2024. Our conclusion on the current half-year financial report is modified because of the possible effects of this matter on those comparative amounts.

We conducted our review in accordance with ASRE 2410: *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110: *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 in the financial statements, which indicates the group incurred a loss after tax of $239,902 for the half-year ended 31 December 2025 and as of that date, the group had net liabilities of $229,902. As stated in Note 1 these events or conditions, along with other matters set forth in Note 1 indicate the existence of a material uncertainty that may cast significant doubt on the group's ability to continue as a going concern. Our conclusion is not further modified in respect of this matter.

HALL CHADWICK (NSW)

GENETIC TECHNOLOGIES LIMITED
ABN 17 009 212 328

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF
GENETIC TECHNOLOGIES LIMITED

Responsibility of the Directors for the Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134: *Interim Financial Reporting* and the *Corporations Regulations 2001.*

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Hall Chadwick

HALL CHADWICK (NSW)
Level 40, 2 Park Street
Sydney, NSW 2000

DREW TOWNSEND
Partner
Dated: 14 September 2026